Occult breast carcinoma presenting as paraneoplastic opsoclonus-myoclonus-ataxia syndrome.

BMJ Case RepSep 16, 2026 (epub)

Syed Adil Hassan, Aswini Bezbaruah, Dipjyoti Payeng et al.

✦ AI-curated · Sources linked

Case in brief

A woman in her sixties presented with subacute opsoclonus and gait ataxia, leading to the diagnosis of opsoclonus-myoclonus-ataxia syndrome (OMAS). Despite extensive imaging, no primary breast lesion was found, revealing only metastatic carcinoma in the left axillary lymph nodes. The patient's neurological symptoms improved significantly after treatment with corticosteroids and intravenous immunoglobulin.

What made this case unusual

This case highlights an atypical presentation of antibody-negative paraneoplastic OMAS associated with occult breast carcinoma, where the malignancy was only evident in axillary lymph nodes.

Diagnostic / clinical pearl

Clinicians should consider the possibility of occult malignancies in patients presenting with opsoclonus-myoclonus-ataxia syndrome, even when initial imaging does not reveal a primary tumor.

Why it matters

Recognizing this association can lead to timely diagnosis and management of underlying malignancies, potentially improving patient outcomes.

Source

Published in BMJ Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.